APOLLO HOSPITALS ENTERPRISE LTD.

This filing from Apollo Hospitals Enterprise Ltd is a notification to the stock exchanges, specifically the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). The content of the filing is contained within an annexure, which is not provided in the extract. The filing is dated September 24, 2026, and includes the company's CIN and a digitally signed name, indicating an official communication.

Apollo Hospitals Enterprise Ltd has submitted its updated Annual Report for the financial year ended March 31, 2026. The report details the company's performance, business portfolio, and strategic initiatives, with a significant focus on technology integration, including AI across the care continuum and new medical technology adoption. Key highlights include the expansion of AI algorithms, adoption of advanced technologies like HyperArc™ and HyperSight™, and strengthened emergency response systems. The company also emphasizes its commitment to preventive care, research and development, and expanding its presence.

Apollo Hospitals Enterprise Limited conducted its 45th Annual General Meeting (AGM) on August 25, 2026, via Video Conferencing. The meeting was attended by 81 members. Key agenda items included the adoption of audited financial statements for FY26, confirmation of interim dividend, and declaration of final dividend. Directors Smt. Sangita Reddy and Dr. Prathap C Reddy, retiring by rotation, were proposed for re-appointment. The reappointment of Dr. Prathap C Reddy as Executive Chairman and Smt. Rama Bijapurkar as Independent Director were also proposed. The company also sought approval to issue redeemable non-convertible debentures up to ₹7,500 million and ratified the remuneration of the Cost Auditor. Both Statutory and Secretarial Auditors' reports were unqualified.

Apollo Hospitals Enterprise Ltd announced its unaudited financial results for the three months ended June 30, 2026, which have undergone a limited review by statutory auditors. The company also approved the appointment of M/s Price Waterhouse Chartered Accountants LLP as its new statutory auditors for a five-year term starting from the conclusion of the 46th AGM in 2027, subject to shareholder approval. The current auditors, M/s Deloitte Haskins & Sells LLP, will continue until the 46th AGM. Additionally, the board noted the proposed transfer of Apollo Healthco Limited's undertaking to its wholly-owned subsidiary, Apollo Consumer Products Limited, via a slump sale. The company also approved the grant of additional stock options under the Apollo ESOP Plan 2024.

Apollo Hospitals Enterprise Ltd announced its unaudited financial results for the three months ended June 30, 2026. The results, both standalone and consolidated, have undergone a limited review by the statutory auditors. The company also approved the appointment of M/s Price Waterhouse Chartered Accountants LLP as its statutory auditors for a five-year term commencing from the conclusion of the 46th AGM in 2027. Additionally, the board noted the proposed transfer of Apollo Healthco Limited's undertaking to its wholly-owned subsidiary, Apollo Consumer Products Limited, via slump sale. Stock options were also granted under the Apollo ESOP Plan 2024.

Apollo Hospitals' consolidated Q1 FY27 (three months to June 30, 2026) revenue rose 21% YoY and 6.6% QoQ to Rs.7,043.5 Cr, with consolidated EBITDA up 28% YoY to Rs.1,092 Cr (margin ~15.5% vs 14.6% a year ago and 15.3% last quarter). Reported PAT for the period (before minority interest, matching the statement's PAT row) was Rs.610.4 Cr, up 38.4% YoY and 10.7% QoQ; the owners-attributable PAT the company headlines in its press release was Rs.580.7 Cr (+34% YoY), the Rs.29.7 Cr gap going to non-controlling interests in subsidiaries such as Apollo HealthCo and AHLL. There were no exceptional items in the quarter on either a standalone or consolidated basis, so the growth is clean — last year's Rs.19.2 Cr labour-code exceptional charge sat only in the FY26 full-year column, not in the Q1 FY26 base. Growth was broad-based. Healthcare Services (hospitals) revenue grew 22% YoY to Rs.3,567 Cr with EBITDA up 20% YoY to Rs.862 Cr, even after absorbing a Rs.38 Cr EBITDA drag from newly launched capacity (Sarjapur plus the Financial District/Sonarpur/Pune/Delhi Oncology cohort); stripping that drag, underlying hospital EBITDA margin expanded over 100bps, consistent with management's guided margin offset from mature hospitals. Apollo HealthCo (pharmacy distribution + digital) grew revenue 20% YoY to Rs.2,977 Cr and lifted EBITDA margin to 6% from ~3.8%, narrowing its PAT loss to Rs.1 Cr from Rs.8 Cr a year ago. On a standalone (parent-only) basis, PAT grew a slower 25.5% YoY to Rs.385.2 Cr versus the consolidated 38.4% — a sizeable gap, since the faster-growing, higher-incremental-margin subsidiaries sit outside the standalone entity. A pre-result preview (Univest) had flagged Q1 FY27 as a 'stable' quarter with revenue seen in a Rs.6,526-7,351 Cr range; the actual Rs.7,043.5 Cr print and 28% EBITDA growth came in ahead of that stable-quarter framing — a beat on the operating line, though no explicit street PAT consensus was found. Against management's own prior guidance (12-14% organic hospital growth plus 3-4% from new beds), Healthcare Services' 22% YoY growth beat the guided range; store-addition pace (151 net new stores this quarter, ~604 annualised vs a 600/year target) and new-bed start-up losses (Rs.38 Cr this quarter vs a guided ~Rs.150 Cr for all of FY27) are both tracking guidance. The one metric trailing its target is Apollo 24/7 GMV, up 23% YoY to Rs.535 Cr against a guided 30% FY27 growth rate. Separately, the board used the results meeting to approve PwC as incoming statutory auditor from the 46th AGM (succeeding Deloitte after two five-year terms), and noted the AHEL-AHL-Keimed Scheme of Arrangement (creating listed entity Apollo Healthtech) has moved to an NCLT sanction petition after June 24, 2026 shareholder/creditor approvals; AHL separately plans to slump-sell its ~Rs.3,610 Cr FMCG distribution undertaking to subsidiary Apollo Consumer Products by around October 1, 2026. Founder-chairman Dr. Prathap Reddy's statement framed the quarter as reflecting 'the strength of our integrated model,' citing the 21% consolidated revenue growth across Healthcare Services, Diagnostics/Retail Health and Digital Health/Pharmacy — numbers that match the filing. Management's framing of steady international patient demand (IPS revenue +26% YoY) and disciplined capacity expansion (5,800 planned new beds over five years, four more hospitals announced in Indore, Dwarka, Delhi and Ranchi) sets up further near-term start-up-loss drag on hospital EBITDA even as the core network's occupancy (70% vs 65% YoY) and ARPP continue to climb. The next checkpoints are Apollo 24/7's GMV trajectory against the 30% FY27 guide, confirmation of digital cash-EBITDA breakeven (guided for this quarter but not separately broken out in this filing), and progress of the Apollo Healthtech demerger through the NCLT.

Apollo Hospitals Enterprise Ltd announced its financial results for the quarter ended June 30, 2026. The company reported a total revenue from operations of ₹28,207.19 lakhs (₹282.07 Cr) and profit after taxes from ordinary activities of ₹2,233.22 lakhs (₹22.33 Cr). Standalone revenue from operations was ₹30,206.70 lakhs (₹302.07 Cr) with a net profit after tax of ₹2,434.27 lakhs (₹24.34 Cr). The company also published notices for its 45th Annual General Meeting and e-voting information.

Apollo Hospitals Enterprise Limited has announced its 45th Annual General Meeting (AGM) to be held on August 25, 2026, at 10:15 AM IST via Video Conferencing. The agenda includes the adoption of audited standalone and consolidated financial statements for the fiscal year ended March 31, 2026. Shareholders will also vote on ratifying an interim dividend of ₹10 per equity share and declaring a final dividend of ₹10 per equity share for FY26. Additionally, the AGM will address the re-appointment of Smt. Sangita Reddy and Dr. Prathap C Reddy as directors retiring by rotation, and the re-appointment of Dr. Prathap C Reddy as Whole-time Director designated as Executive Chairman for two years.

Apollo Hospitals Enterprise Limited has announced its 45th Annual General Meeting (AGM) to be held on Tuesday, August 25, 2026, at 10:15 AM IST. The meeting will be conducted via Video Conferencing (VC) / Other Audio-Visual Means (OAVM). Key agenda items include the adoption of audited standalone and consolidated financial statements for the financial year ended March 31, 2026. The AGM will also address the confirmation of an interim dividend of ₹10 per equity share and the declaration of a final dividend of ₹10 per equity share for the same financial year. Furthermore, the re-appointment of Smt. Sangita Reddy and Dr. Prathap C Reddy as retiring directors, and the re-appointment of Dr. Prathap C Reddy as Whole-time Director designated as Executive Chairman for two years, will be considered.

Apollo Hospitals Enterprise Ltd has announced that its Board of Directors will convene on August 12, 2026. The primary agenda item is the consideration and approval of the unaudited financial results, both standalone and consolidated, for the first quarter ended June 30, 2026. Additionally, the meeting will address other related matters. In line with SEBI regulations, the trading window for promoters, directors, and designated employees will remain closed from July 1, 2026, until 48 hours after the announcement of the financial results, extending up to August 14, 2026.